Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Apellis Pharmaceuticals, Inc is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 391 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$56.28|
|52-week range||$26.28 - $71.09|
|50-day moving average||$63.90|
|200-day moving average||$51.41|
|Wall St. target price||$79.47|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.32|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-19.42%|
|3 months (2021-05-03)||12.11%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
|Revenue TTM||$250.6 million|
|Gross profit TTM||$-74,325,000|
|Return on assets TTM||-19.97%|
|Return on equity TTM||-231.58%|
|Market capitalisation||$5.4 billion|
TTM: trailing 12 months
There are currently 6.2 million Apellis Pharmaceuticals shares held short by investors – that's known as Apellis Pharmaceuticals's "short interest". This figure is 4.9% up from 5.9 million last month.
There are a few different ways that this level of interest in shorting Apellis Pharmaceuticals shares can be evaluated.
Apellis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Apellis Pharmaceuticals shares currently shorted divided by the average quantity of Apellis Pharmaceuticals shares traded daily (recently around 919174.04129794). Apellis Pharmaceuticals's SIR currently stands at 6.78. In other words for every 100,000 Apellis Pharmaceuticals shares traded daily on the market, roughly 6780 shares are currently held short.
However Apellis Pharmaceuticals's short interest can also be evaluated against the total number of Apellis Pharmaceuticals shares, or, against the total number of tradable Apellis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Apellis Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Apellis Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1036% of the tradable shares (for every 100,000 tradable Apellis Pharmaceuticals shares, roughly 104 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Apellis Pharmaceuticals.
Find out more about how you can short Apellis Pharmaceuticals stock.
We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $26.28 up to $71.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.4887. This would suggest that Apellis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Apellis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.